These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38948071)

  • 21. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
    Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X; Gao L; Wang B; Hu J; Yu Y; Gu B; Xiang L; Li X; Li H; Zhang T; Wang Y; Ma C; Dong J; Lu J; Lucas A; Chen H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
    Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma.
    Zhang X; Zheng P; Meng B; Zhuang H; Lu B; Yao J; Han F; Luo S
    Clin Exp Med; 2024 Jun; 24(1):129. PubMed ID: 38884870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
    Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
    Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.
    Yan F; Zhu B; Shi K; Zhang Y; Zeng X; Zhang Q; Yang Z; Wang X
    Cancer Sci; 2024 Aug; 115(8):2553-2564. PubMed ID: 38877825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy.
    Xu W; Hu M; Lu X; Lao Y; Ma N; Wang Y; Li J; Chen X; Liu S; Liu J; Zhu W; Yang H
    Int J Biol Sci; 2024; 20(10):3942-3955. PubMed ID: 39113701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
    Weng J; Wang Z; Hu Z; Xu W; Sun JL; Wang F; Zhou Q; Liu S; Xu M; Xu M; Gao D; Shen YH; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    Cancer Res; 2024 Jun; 84(11):1817-1833. PubMed ID: 38484085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.
    Gu J; Yu Z; Tang X; Chen W; Deng X; Zhu X
    Int J Hyperthermia; 2024; 41(1):2373319. PubMed ID: 38955354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. POSTN
    Wang H; Liang Y; Liu Z; Zhang R; Chao J; Wang M; Liu M; Qiao L; Xuan Z; Zhao H; Lu L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
    Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
    Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination.
    Chen S; Zhao L; Liu J; Han P; Jiang W; Liu Y; Hou J; Wang F; Li J
    Cancer Lett; 2024 Aug; 598():217105. PubMed ID: 38971490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.